Median Local Anaesthetic dose (MLAD) of Intrathecal Prilocaïne in total hip arthroplasty with the anterior approach.

Phase 4

Completed

Conditions: Anaesthesia
10023213

Registration Number: NL-OMON42912

Lead Sponsor: Reinier de Graaf Groep

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 25

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:;- ASA I to III
- 18y or older
- Primary uncemented THA with anterior approach
- Willing to participate
- Speaking Dutch language

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:;- Hypersensitivity to local anesthetics or any of the other excipients of prilocaine
- Any other contraindications relate to intrathecal anesthesia
- CNS disease, e.g. meningitis, tumor, poliomyelitis, cerebral hemorrhage
- Spinal stenosis and diseases or recent trauma to the cervical column
- Sepsis
- Pernicious anemia with symptoms related to cervical degradation
- Pyogenic infections of the skin close to the injection site
- Cardiogenic or hypovolemic shock
- Disturbance in coagulation or treatment with anti-coagulants
- Patient is participating in a medicinal study
- Noncompliant to intrathecal anesthesia
- Patients who are incompetent to decide

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Determination of the ED50 (95%CI) of prilocaine administered intrathecally in<br /><br>THA with anterior approach that allows direct post-operative mobilization and<br /><br>will accommodate sufficient anesthesia during surgery. </p><br>

Secondary Outcome Measures